Key Highlights
- Novo Nordisk (NVO) has entered a partnership with Orbis Medicines valued at up to $1.4 billion for drug discovery
- The collaboration focuses on developing oral therapies for cardiometabolic conditions that currently require injections
- Orbis will leverage its nGen AI platform to create innovative oral macrocycle medications
- The Danish pharmaceutical giant will take a strategic equity stake in Orbis as part of the arrangement
- Early preclinical data shows these macrocycles achieving oral bioavailability rates of up to 18%
On Thursday, [[LINK_START_1]]Novo Nordisk (NVO)[[LINK_END_1]] and Copenhagen-based biotech firm Orbis Medicines unveiled a comprehensive drug discovery and licensing partnership valued at up to $1.4 billion. The collaboration aims to create oral medication alternatives for cardiometabolic diseases.
This strategic alliance concentrates on medical conditions presently requiring injectable medications. The primary objective involves transforming these injection-based treatments into convenient oral formulations that patients can take by mouth.
Through its AI-powered nGen discovery platform, Orbis will identify and develop macrocyclesādistinctive ring-structured molecular compounds. These specialized molecules hold promise for targeting disease mechanisms that conventional small-molecule pharmaceuticals struggle to address.
According to Orbis CEO Morten Graugaard, the company’s synthetically produced macrocycles have demonstrated oral bioavailability rates reaching 18% during preclinical testing. This metric indicates the percentage of an orally administered drug that successfully enters the bloodstream.
“Together with Novo, we have an opportunity to unlock a new generation of oral medicines for cardiometabolic diseases,” Graugaard said.
Financial Terms and Investment
The partnership encompasses initial payments, milestone-based compensation tied to development progress and commercial success, plus tiered royalty arrangements on eventual product revenues. Specific details regarding the allocation of the $1.4 billion total remain undisclosed.
Beyond the collaboration terms, Novo Nordisk plans to make a strategic equity investment in the privately held Orbis. The exact dollar amount of this investment has not been publicly revealed.
This partnership complements Novo’s existing capabilities in oral peptide delivery, particularly its SNAC technology platform. The pharmaceutical giant obtained this proprietary technology through its 2020 acquisition of Emisphere Technologies, a U.S.-based drug delivery specialist.
According to a company representative, Novo remains committed to advancing innovation in oral drug delivery through a combination of in-house research initiatives and strategic external collaborations.
Industry Momentum for Oral Macrocycles
This announcement arrives amid growing pharmaceutical industry interest in oral macrocyclic therapeutic compounds.
Earlier this year in March, Johnson and Johnson (JNJ) secured U.S. regulatory clearance for Icotyde, an oral macrocyclic peptide indicated for treating plaque psoriasis. Several months later in July, Merck (MRK) obtained approval for Lipfendra, an oral macrocyclic peptide designed to reduce cholesterol levels.
Headquartered in Copenhagen, Orbis positions its nGen platform as a purpose-built artificial intelligence system engineered to accelerate the identification and optimization of macrocycle drug candidates.
The multi-target nature of this partnership indicates that both organizations will pursue opportunities across multiple therapeutic areas within cardiometabolic medicine, rather than limiting their efforts to a single compound or specific condition.
[[LINK_START_3]]Novo Nordisk[[LINK_END_3]] has not provided detailed commentary on how this collaboration integrates with its overall development portfolio, though the company acknowledged it extends their ongoing oral drug delivery research.
Following Thursday’s announcement, NVO shares attracted investor attention as market participants evaluated the potential for this partnership to diversify Novo’s product pipeline beyond its established injectable GLP-1 therapy portfolio.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
